Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betula lenta pollen extract is an allergenic extract derived from the pollen of the Betula lenta (black or cherry birch) tree. It is used for both the diagnosis (via skin testing) and treatment (via immunotherapy) of allergies to birch pollen. [19, 23] As a non-standardized biological extract, it contains various allergenic proteins from the pollen. [23] Administration is typically through injection (subcutaneous, intradermal, or percutaneous). The principle of immunotherapy involves administering gradually increasing doses of the allergen to modulate the immune system's response, leading to increased tolerance and a reduction in allergic symptoms upon environmental exposure. [4, 9] The product is marketed by companies such as ALK-Abello, Inc. and Allermed Laboratories, Inc.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Betula lenta pollen extract.